Skip to content
Medical Health Aged Care

BrainTrack app wins major iAward

Dementia Australia 2 mins read

BrainTrack, a free app that helps you privately monitor and understand changes in cognition over time, won a major award at the recent ACT iAwards ceremony.

BrainTrack, developed by Dementia Australia and Deakin University’s Applied Artificial Intelligence Institute (A²I²) Institute, won the community/not-for-profit category at the awards ceremony held in Canberra.

Dementia Australia CEO Maree McCabe AM said it was thrilling to receive the award, which recognised of how BrainTrack was promoting early diagnosis of dementia.

“With more than 400,000 Australians living with dementia – which is projected to increase to more than 800,000 people by 2058 – improving early diagnosis must be a priority,” Ms McCabe said.

The Australian Information Industry Association iAwards program celebrates excellence in the Australian digital ecosystem.

BrainTrack helps individuals explore common cognitive concerns and provides brain health information through fun, travel-themed games that have been adapted from validated cognitive testing. Users can share their results with their GP to support the early identification of cognitive changes over time that may warrant further testing.

Co-Director of Deakin University’s A²I², Alfred Deakin Professor Kon Mouzakis said he was proud to have worked with Dementia Australia in developing BrainTrack from concept through to it now being supported by a Medical Research Future Fund grant.

Since being released in October 2022 BrainTrack has been downloaded by more than 50,000 people, including from the US, UK, New Zealand and Canada.

“I congratulate the incredible team behind this groundbreaking tool that is increasing the understanding of dementia and raising awareness about the importance of monitoring and talking about brain health,” Ms McCabe said.

The development of BrainTrack was funded by the Australian Government.

BrainTrack is available for download for free through the Apple App Store or Google Play. For more information, please visit www.dementia.org.au/braintrack or call the National Dementia Helpline on 1800 100 500.

To view all Dementia Australia’s awards and recognition go to https://www.dementia.org.au/about-us/dementia-australia/awards-and-recognition

Dementia Australia is the source of trusted information, education and services for the estimated more than 400,000 Australians living with dementia, and the more than 1.5 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: David Gear, [email protected], 0427 204 297

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.


Contact details:

David Gear, [email protected], 0427 204 297

Media

More from this category

  • Medical Health Aged Care
  • 17/03/2026
  • 12:03
Monash University

New microlearning video series to support the safer use of psychotropic medications in residential aged care

Researchers at Monash University and Flinders University have launched a series of microlearning education videos designed to support safer, more appropriate use of psychotropic medications for people living with dementia and in residential aged care. The video series includes 12 short, practical modules (approximately 5-7 minutes each) covering key topics including initiation, monitoring and discontinuation of antipsychotics, antidepressants and benzodiazepines. The videos are the latest in a suite of practical resources designed to support translation of key recommendations and good practice statements from the Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living with Dementia and…

  • Biotechnology, Medical Health Aged Care
  • 17/03/2026
  • 11:32
RMIT University

New smart bandage could heal and monitor wounds at the same time

Australian researchers haveunlockedthe possibility of creating smart wound dressingsthat enable real-time monitoring while also being able to deliver healingagentsin one simple, scalable platform. Chronic…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/03/2026
  • 10:25
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Advances StemSmart(TM) Manufacturing Scale-Up as Phase 2 Crohn’s Disease Trial Preparations Progress

Perth, Australia – 17 March 2026 | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has reached an important development milestone with the commencement of the first technology transfer manufacturing run of its patented StemSmart™ mesenchymal stem cell (MSC) process at leading Australian cell therapy manufacturer Q-Gen Cell Therapeutics. The initiation of the manufacturing run represents a key step in the transfer of the StemSmart™ manufacturing process to a large-scale clinical contract manufacturer that is then capable of providing adequate supply for Phase 2 clinical trials and future commercialisation. Q-Gen Cell Therapeutics, located within the QIMR Berghofer Medical Research Institute in Brisbane, is one…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.